Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012

Publications from Roche and a case-control study suggest that there is no evidence, or plausible mechanism of action, to link neuropsychiatric adverse events to Tamiflu (oseltamivir).1 2 Cochrane Collaborators, the BMJ , and others, however, contend that many of Roche’s data remain unavailable.3 We examined neuropsychiatric adverse events associated with oseltamivir in the US FDA’s Adverse Event Reporting System (FAERS) from October 1999 to August 2012 by using a data mining platform (RxFilterTM; www.AdverseEvents.com4) to generate case report …